RVLPQ (RVL Pharmaceuticals) YoY EBITDA Growth: -62.02% (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RVLPQ RVL Pharmaceuticals PLC RVLPQ
12 GF Score
Price $0.00
View Full Analysis

What is RVL Pharmaceuticals YoY EBITDA Growth?

RVL Pharmaceuticals RVLPQ -90.00% 12 YoY EBITDA Growth is -62.02% as of Jun. 2023. GuruFocus rates RVLPQ with a GF Score™ of 12/100.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. RVL Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Jun. 2023 was -62.02%.

RVL Pharmaceuticals's EBITDA per Share for the three months ended in Jun. 2023 was $-0.21.

RVL Pharmaceuticals YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for RVL Pharmaceuticals's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RVL Pharmaceuticals YoY EBITDA Growth Chart

RVL Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
YoY EBITDA Growth
Get a 7-Day Free Trial -62.90 -1,081.94 73.00 9.14 48.56

RVL Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 53.60 50.88 35.81 28.07 -62.02
RVLPQ
12GF Score
RVL Pharmaceuticals PLC RVLPQ
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RVL Pharmaceuticals YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

RVL Pharmaceuticals's YoY EBITDA Growth for the fiscal year that ended in Dec. 2022 is calculated as:

YoY EBITDA Growth (A: Dec. 2022 )
=(EBITDA per Share (A: Dec. 2022 )-EBITDA per Share (A: Dec. 2021 ))/ | EBITDA per Share (A: Dec. 2021 ) |
=(-0.537--1.044)/ | -1.044 |
=48.56 %

RVL Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Jun. 2023 is calculated as:

YoY EBITDA Growth (Q: Jun. 2023 )
=(EBITDA per Share (Q: Jun. 2023 )-EBITDA per Share (Q: Jun. 2022 )) / | EBITDA per Share (Q: Jun. 2022 )) |
=(-0.209--0.129)/ | -0.129 |
=-62.02 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -62.02% mean?
RVL Pharmaceuticals (RVLPQ) has a YoY EBITDA Growth of -62.02% as of Jun. 2023. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for RVL Pharmaceuticals and its competitors.
Is RVL Pharmaceuticals' YoY EBITDA Growth too high?
RVL Pharmaceuticals' current YoY EBITDA Growth is -62.02%. Overall, RVL Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does RVL Pharmaceuticals' YoY EBITDA Growth compare to SNPX and THAR?
RVL Pharmaceuticals' YoY EBITDA Growth of -62.02% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for RVL Pharmaceuticals and its competitors. RVL Pharmaceuticals's current YoY EBITDA Growth is -62.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RVL Pharmaceuticals stock overvalued right now?
RVL Pharmaceuticals (RVLPQ) has a current YoY EBITDA Growth of -62.02%. The current YoY EBITDA Growth is -62.02%. RVL Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For RVL Pharmaceuticals (RVLPQ), the current YoY EBITDA Growth is -62.02% as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RVL Pharmaceuticals Business Description

Address 400 Crossing Boulevard, Bridgewater, NJ, USA, 08807
RVL Pharmaceuticals PLC is a pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular medicine and medical aesthetics therapeutic areas. Its revenues consist of product sales, royalty revenues and licensing revenue.
12GF Score

Get the complete analysis for RVLPQ

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price